Managing Diabetes - Q4 2021

Q4 2021 | A promotional supplement distributed on behalf of Mediaplanet, which takes sole responsibility for its content

Read more at www.healthawareness.co.uk

A Mediaplanet campaign focused on

Managing Diabetes

Jordan Thompson, professional cricketer and ambassador for Diabetes UK, shares his experiences of living with type 1 diabetes with the aim of encouraging others to seek help.

Read more on P6 ©Getty images

02

“We are on the cusp of a breakthrough with immunotherapies.”

Dr Lucy Chambers Head of Research Communications, Diabetes UK

Stress

Sleep

10

“The centenary of the discovery of insulin has attracted greater attention to the diabetes cause.”

Professor Andrew Boulton President, International Diabetes Federation

Activity

Nutrition

It all fits together

A PROMOTIONAL SUPPLEMENT DISTRIBUTED ON BEHALF OF MEDIAPLANET, WHICH TAKES SOLE RESPONSIBILITY FOR ITS CONTENTS

How immunotherapies could be the next breakthrough for type 1 diabetes

This year marks the centenary of the discovery of insulin, a breakthrough moment when type 1 diabetes was turned from a death sentence into a condition that can be managed.

T WRITTEN BY

Dr Lucy Chambers Head of Research Communications, Diabetes UK

he discovery has saved millions of lives across the type 1 diabetes from developing in those at high risk; world but, as anyone living with type 1 will tell preserve the beta cells that are yet to be destroyed in people you, managing type 1 with insulin therapy can be with a new type 1 diagnosis; and eventually, form part of a relentless and frustrating. It’s extremely labour cure when used alongside beta cell replacement therapy in intensive and avoiding dangerous blood sugar lows and people already living with type 1. highs are near impossible.

Yet today insulin remains the only Making immunotherapies a reality treatment available for type 1 diabetes.

Currently, there are no licensed For too long we’ve relied on a treatment immunotherapies for type 1 diabetes in A positive outcome would that deals only with the symptoms of the UK or anywhere else in the world. type 1 diabetes – the lack of insulin. To Diabetes UK is funding research and mean the world’s first transform people’s health and lives, we working with healthcare partners to licensed immunotherapy for need treatments that target the root cause make immunotherapies a reality in type 1 diabetes and a step of type 1 diabetes – the immune system’s the UK as soon as possible. We are on attack on the insulin-producing beta the cusp of a breakthrough. The UK’s closer to a cure. cells in the pancreas. This is the hope for drug approval agency, the MHRA, is immunotherapies. right now considering the evidence on an immunotherapy called teplizumab. Clinical trials Immunotherapies transforming future treatment have shown that teplizumab can delay the onset of type Immunotherapies, currently being tested in clinical trials, 1 diabetes in those at high risk. The MHRA’s decision is are designed to reprogram the immune system so that it no expected in 2022. A positive outcome would mean the longer destroys insulin-producing beta cells. The hope is world’s first licensed immunotherapy for type 1 diabetes that in the future, immunotherapies will be used to prevent and a step closer to a cure.

@HealthawarenessUK

@MediaplanetUK

Contact information: uk.info@mediaplanet.com or +44 (0) 203 642 0737

Please recycle

Project Manager: Lauren Sharp lauren.sharp@mediaplanet.com Business Development Manager: Gabrielle Dunn Managing Director: Alex Williams Head of Business Development: Ellie McGregor Head of Production: Kirsty Elliott Designer: Thomas Kent Design & Content Assistant: Aimee Rayment Digital Manager: Harvey O’Donnell Paid Media Manager: Jonni Asfaha Social & Web Editor: Henry Phillips Digital Assistant: Carolina Galbraith Duarte All images supplied by Gettyimages, unless otherwise specified

02

MEDIAPLANET

READ MORE AT HEALTHAWARENESS.CO.UK

A PROMOTIONAL SUPPLEMENT DISTRIBUTED ON BEHALF OF MEDIAPLANET, WHICH TAKES SOLE RESPONSIBILITY FOR ITS CONTENTS

We want to help empower people with cardiometabolic conditions such as diabetes so they can better manage their health and wellbeing.

Image provided by Fitbit

Encouraging better diabetes management through wearable technology Blood glucose logging could help to create a holistic view of the impact diabetes can have on daily life.

WRITTEN BY Nicola Maxwell Head of Fitbit Health Solutions in Europe, the Middle East and Africa

WRITTEN BY Emma Elvin Senior Clinical Advisor, Diabetes UK

T

he latest insights from Diabetes UK show that over 4.9 million people are currently living with diabetes in the UK with rates almost doubling in the last 15 years.1 At the current prevalence rates, the NHS spends around £10 billion on average each year in managing and treating the condition which will also increase alongside growing rates. However, research consistently shows that combined lifestyle interventions can be effective in reducing the risk of type 2 diabetes by ~50%.2,3 The pandemic has significantly impacted patient access to healthcare and millions of patients with diabetes have been unable to get regular health checks with their healthcare team.4 With many GP appointments still being held remotely,5 wearable devices are increasingly being piloted to help people monitor long-term health conditions and as a result, the value of wearable devices to help people better manage such longterm health conditions is becoming increasingly recognised.6 Focussing on holistic health Fitbit has a multi-year partnership with Diabetes UK to help raise awareness of the condition and help educate people on the importance of getting to know their body and how it works, in order to encourage behaviour changes that may help lessen the risk of developing type 2

READ MORE AT HEALTHAWARENESS.CO.UK

diabetes and help people to understand their diabetes, in addition to benefiting overall health and wellbeing.7 In November, people in the UK will be able to use a new blood glucose logging tool from Fitbit, to help those living with diabetes. They will be able to track their glucose levels by manually logging them in the app throughout the day. Users can then view those levels right in the app alongside other metrics from Fitbit such as physical activity, sleep and their logged nutrition, to help better manage their holistic health and wellness all in one place. Within the app, users will be able to set personalised ranges so they can see when they are outside their target range to better identify important changes. They can also receive reminders to log their glucose levels so they can view their trends over time.

“We want to help empower people with cardiometabolic conditions such as diabetes so they can better manage their health and wellbeing,” says Nicola Maxwell, Head of Fitbit Health Solutions in EMEA. “We hope that by making the blood glucose logging feature available through our app, it will help provide accessibility for more people. We are passionate that our work with Diabetes UK will continue to raise awareness for and help improve the health of those living with diabetes.”

Useful tools and technology The increasing rates of diabetes,

coupled with the growth of patient self-management and wider adoption of digital health services,8 highlights the need for tools and technology to help people with diabetes better manage their condition.

“Often when people are diagnosed with diabetes, they feel overwhelmed and in reality, have to spend most of the time self-managing their condition,” says Emma Elvin, Senior Clinical Advisor at Diabetes UK. “By logging their blood glucose levels in the Fitbit app, users can see what types of lifestyle factors affect their diabetes and how their blood sugar fluctuates.

Seeing all their trends in one place, can help to give people a greater sense of control and begin to make small changes to help them manage their diabetes more effectively.”

Paid for by Fitbit

* The Blood Glucose feature is not a replacement for medical advice and is not intended to diagnose or treat any medical condition.

It is intended to simply help you monitor and keep track of your information. You should talk to your healthcare provider for more guidance on blood glucose management. ** This feature is rolling out to all UK users, English only in November.

References 1. https://www.diabetes.org.uk/about_us/news/diabetes-diagnosesdoubled-prevalence-2021 2. https://www.diabetes.org.uk/resources-s3/2017-11/diabetes%20 uk%20cost%20of%20diabetes%20report.pdf 3. https://www.diabetes.org.uk/about_us/news/diabetes-diagnosesdoubled-prevalence-2021 4. https://www.nursinginpractice.com/clinical/diabetes/millions-withdiabetes-at-risk-due-to-covid-backlog/ 5. https://www.bbc.co.uk/news/health-58670560 6. https://www.bmj.com/content/372/bmj.n413 7. https://mrc.ukri.org/documents/pdf/diabetes-uk-facts-andstats-june-2015/#:~:text=DIAGNOSED%20Around%20700%20 people%20a,1.4%20million%20to%203.3%20million4.

8. https://www.medicaldevice-network.com/comment/pandemicimportance-telemedicine/

Find out more at fitbit.com/global /uk/home

MEDIAPLANET

03

A PROMOTIONAL SUPPLEMENT DISTRIBUTED ON BEHALF OF MEDIAPLANET, WHICH TAKES SOLE RESPONSIBILITY FOR ITS CONTENTS

Why life-changing tech should be accessible to people living with type 2 diabetes Flash glucose monitoring is life-changing technology for people with diabetes.

That’s why it should be available free to anyone who needs it, says Ken Tait who is living with type 2 diabetes.

K INTERVIEW WITH

Ken Tait Living with type 2 diabetes WRITTEN BY

Tony Greenway

en Tait was diagnosed with type 2 diabetes in 1999 Flash glucose monitoring can change lives and save NHS costs and, since then, routine finger prick testing has Unfortunately, Ken was only able to use the flash glucose become an established part of his life. Anyone in the monitoring system full-time for four months. He now same position will know that finger pricking many restricts it to when he is on holiday or if he is going to be on times a day is an important way to check glucose levels, but his own for an extended period. it can also be painful, time-consuming and inconvenient.

“Many people with type 1 diabetes have access to flash “I have a saying,” says Ken. “‘I want to be glucose monitoring,” he notes. “Sadly, this able to manage my diabetes, rather than technology isn’t free for people living with have my diabetes manage me.’” type 2 diabetes, so the cost of using it all the Flash glucose monitors allow people time was just too prohibitive for me. Yet it with diabetes to immediately see if their is life-changing and should be available on The cost of using it all the sugar levels are within the correct range the NHS to anyone who needs it. In fact, I time was just too prohibitive by scanning a sensor on the back of their think it would actually save the NHS money for me. Yet it is life-changing upper arm. The sensor is scanned using in the long-run because if it helps people and should be available on the better manage their diabetes — of whatever either a reader or an app on a phone, they then receive a notification if their glucose type — then it will ultimately reduce NHS to anyone who needs it. goes above or drops below a certain level, complications and hospitalisations.” allowing them to take appropriate action.

Ken believes that people living with type “Quality of life improves so much with a flash glucose 2 diabetes can be stigmatised by the medical establishment, monitoring system” says Ken. “Finger pricking only gives media and wider society. That must change, he says. you a snapshot of a moment in time, so you don’t know “Everything seems to be geared towards those living with if your levels are going up or down; whereas with a flash type 1. I think it’s because there’s a narrative that all type glucose monitoring system, you can read them whenever 2 patients can ‘reverse it’ if they would only change their you want.” lifestyles. However, that’s just not the case.”

YOU CAN DO IT

Could you give up painful finger pricking?2,3 No finger pricks4 – You can manage your diabetes painlessly5 Optional Glucose Alarms – Know the minute your glucose is too low or too high

WITHOUT LANCETS1

Images are for illustrative purposes only. Not actual patient or data.

1. Scanning the sensor does not require lancets. 2. Vincze G. et al. Diabetes Educ. (2004);30(1):112-125. 3. Wagner J. et al. Diabetes Technol Ther. (2005);7(4):612-619. 4. Finger pricks are required if glucose readings and alarms do not match symptoms or expectations. 5. Haak, Thomas., et al. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: multicenter, open-label randomized controlled trial. Diabetes Therapy 8.1 (2017): 55-73. iPhone is a trademark of Apple Inc. © 2021 Abbott. FreeStyle, Libre, and related brand marks are marks of Abbott. ADC-48116 v1.0 11/21.

Start your 14 day free trial today, please visit Sample.FreeStyle.Abbott

7869 - ADC - WDD Adverts - GUARDIAN AD - 106x530mm - AW.indd 1

04

MEDIAPLANET

READ MORE AT HEALTHAWARENESS.CO.UK

A PROMOTIONAL SUPPLEMENT DISTRIBUTED ON BEHALF OF MEDIAPLANET, WHICH TAKES SOLE RESPONSIBILITY FOR ITS CONTENTS

Widening access to better tech for those living with type 2 diabetes Ultimately, it’s not a question of should this technology be accessible to those living with type 2 diabetes, it’s a question of when.

E

ffective diabetes technology has the power to revolutionise lives. Take flash glucose monitoring, which has been an enormous advancement for many people living with type 1 diabetes. Instead of conducting multiple painful finger prick tests a day to check their glucose levels, they can now simply scan a sensor on the back of their upper arm (although, admittedly, this technology does not do away with the need for finger pricks completely).

Dr Emma Wilmot — Founder of the ABCD Diabetes Technology Network UK (DTN-UK), an organisation that supports the delivery of life-improving diabetes technologies — is an enthusiastic advocate of flash glucose monitoring and marvels at its take-up rate.

“The device first became available in 2014 and was available on the NHS drug tariff in 2017,” she notes. “In 2021, over half of those living with type 1 diabetes now have access to this technology.” Criteria for access tend to be related to those who are required to monitor their glucose levels frequently; those who have problematic low glucose levels; and those who may have an occupational or psychosocial indication for using the device.

Flash glucose monitoring should be accessible to more people with insulin-treated type 2 diabetes to make management of their condition easier — and save hospital admissions.

Some people with type 2 diabetes can qualify for the technology through the current criteria — such as people on haemodialysis and those who have learning difficulties.

However, the Diabetes Technology Network have recommended wider access to flash glucose monitoring which includes people with insulin-treated type 2 diabetes.

Tech that makes effective self-management a reality This makes perfect sense, argues Dr Wilmot, because flash glucose monitoring has been shown to result in a reduction in high glucose levels for those with insulin-treated type 2 diabetes. It can also reduce acute events and hospitalisations for those living with type 2 diabetes, thereby making savings to local health economies. Plus — because it’s a digital device — it can potentially support remote consultations.

“The difficulty is that the number of people with type 2 diabetes is substantially greater than the number of people with type 1 diabetes and securing funding to deliver this technology on a wider scale may be challenging,” says Dr Wilmot.

Ultimately, it’s not a question of should this technology be accessible to those living with type 2 diabetes, says Dr Wilmot. It’s a question of when. “We now have the technologies available to make monitoring of glucose painless and easy, making effective self-management a reality, without the need for multiple finger pricks.

From my perspective, it’s just a matter of time.”

INTERVIEW WITH

Dr Emma Wilmot Founder, Diabetes Technology Network UK (DTN-UK) Consultant Diabetologist, University Hospitals of Derby and Burton NHS FT Honorary (clinical) Associate Professor, University of Nottingham

WRITTEN BY

Tony Greenway

ALARM. SCAN. ACT. 05/11/2021 17:42

READ MORE AT HEALTHAWARENESS.CO.UK

MEDIAPLANET

05

A PROMOTIONAL SUPPLEMENT DISTRIBUTED ON BEHALF OF MEDIAPLANET, WHICH TAKES SOLE RESPONSIBILITY FOR ITS CONTENTS

Q&A Don’t let diabetes stop you from achieving your goals Jordan Thompson, ambassador for Diabetes UK and professional cricketer, was diagnosed with type 1 diabetes in 2013. He wants to share his experiences with the aim of encouraging others to seek help.

What impact has your diagnosis had on your life?

I would say that being diagnosed has had a positive effect on me. At first, I didn’t know if I could play sport, let alone professionally. However, I was so determined to look after myself whilst trying to get to the highest level in cricket possible.

There’s always the occasional hindrance that type 1 brings. For example, taking an insulin pen and a packet of fruit pastilles everywhere can sometimes be a bit of a nuisance, but I’ve got better at managing it.

What is the biggest challenge you have faced in managing your diabetes and playing cricket?

The biggest challenge for me is just making sure that my blood sugar levels behave whilst I’m playing or training.

All the coaching staff and my teammates know that I have type 1, so they always look out for me and make sure that I’m ok. It is important that everyone knows about your condition and understands it.

In the early days of my diagnosis, my teammates didn’t really understand what type 1 was. Now if I need sugar, then they’re always there to quickly get me a Lucozade or Red Bull and then I can carry on as normal.

What advice would you give to others going through a similar experience?

My advice to others living with type 1 diabetes is to try and be positive. We have such a tricky condition that has a mind of its own at times. So, it is important not to be hard on yourself when you have a bad day or two.

In sporting environments, it’s important to make sure everyone knows about your situation and that they know what to do in an emergency.

Overall, enjoy yourself. It’s a barrier that we can all overcome, with a couple of bumps in the road. But we are always trying our best!

WRITTEN BY Jordan Thompson Diabetes UK Ambassador

06

MEDIAPLANET

Why we’re at a ‘tipping point’ moment for diabetes care Every diagnosis of diabetes is life changing. The relentlessness of the condition and the ever-present fear of serious and life-altering complications is a lifelong reality for millions of families across the UK.

D

iagnoses of diabetes have doubled in the last 15 years – and currently almost 4.1 million people in the UK are diagnosed with some form of the condition. In addition, we estimate that a further 850,000 are living with type 2 diabetes but are yet to be diagnosed, while 13.6 million are at increased risk of developing type 2 diabetes.

We estimate that a further 850,000 are living with type 2 diabetes but are yet to be diagnosed, while 13.6 million are at increased risk of developing type 2 diabetes.

Why action is needed now Worryingly, new analysis by Diabetes UK has highlighted how this trend of rising diagnoses is very much on course to continue – unless urgent action is taken.

Our latest projections are based on analysis of Public Health England and The Association of Public Health Observatories’ diabetes prevalence projection models. They reveal that up to 5.5 million adults in the UK – nearly 10% of the projected adult population – will be living with diabetes by 2030, if further action is not taken.

Our message is simple: unless the UK Government commits to urgently and sustainably investing in diabetes care and prevention, the country is on course to reach a diabetes tipping point, with devasting human consequences.

What can be done?

We are calling on the UK Government to: • Make more funding available to enable more people to avoid a diagnosis of type 2 through increasing access to proven preventative measures such as the NHS Diabetes Prevention Programme.

• Significantly expand access to interventions to help people diagnosed with type 2 diabetes go into remission where possible, such as low-calorie weight-management programmes and bariatric surgery.

• Urgently address post-pandemic backlogs, to ensure swift recovery of diagnoses of type 2 diabetes and that people with all types of diabetes have access to the individualised care and treatment they need, to minimise their risk of diabetes complications.

We don’t want our prediction to become a reality and it doesn’t have to become one. What we need to see is the will, grit and determination from government to halt this crisis in its tracks and improve the future health of our nation for generations to come.

For further information on our Diabetes Is Serious campaign visit: diabetes.org.uk

WRITTEN BY Helen Kirrane Head of Policy, Campaigns and Mobilisation, Diabetes UK

READ MORE AT HEALTHAWARENESS.CO.UK

A PROMOTIONAL SUPPLEMENT DISTRIBUTED ON BEHALF OF MEDIAPLANET, WHICH TAKES SOLE RESPONSIBILITY FOR ITS CONTENTS

ethnic minorities, and that training on cultural competence should be integral in the development of healthcare professionals. Across the health system, more robust ethnicity data is needed to ensure the NHS has a fuller picture of the inequalities that exist in diabetes care. NHS recruitment and development also need to adapt to ensure greater diversity among NHS decision-makers, to better reflect the populations they serve.

Urgent change is needed for ethnic minorities living with diabetes

W WRITTEN BY Shannon Rush, Diabetes Business Unit Leader, Lilly UK, Ireland And Northern Europe

hilst there have been incredible advances in diabetes treatment, care and management over the past 100 years, these have not been felt equally across society.

This is especially the case for Black African, Black Caribbean and South Asian ethnic groups who are overrepresented in the population living with diabetes.1 They tend to develop type 2 diabetes at a younger age and are at greater risk of developing associated complications.1,2 At Lilly, we are acutely aware of this and are determined to play our part in bringing about change. For me, the commitment is personal. I have family members living with diabetes, and my role as a caregiver makes me

determined to do what I can to help make life better for those living with diabetes.

Addressing health inequalities I know that to address these health inequalities for ethnic minority groups, we need to work together across the diabetes community to bring about tangible change. I’m proud to have recently brought together a steering group of healthcare professionals, community group representatives and people living with diabetes to discuss the challenges and recommend actions.

We realised that even the way we talk about diabetes prevention and management needs to change to better resonate from people from

Paid for by Eli Lilly and Company

Activating change in diabetes care In collaboration with those who attended the discussion, Lilly is producing a ‘Charter for Change’ which we will use to engage health and political stakeholders to highlight the urgent need for change to support Black African, Black Caribbean and South Asian people living with diabetes.

This article has been paid for and authored by Eli Lilly and Company. PP-LD-GB-1389 October 2021.

References 1. Diabetes UK. Diabetes Statistics. Available at: https://www. diabetes.org.uk/professionals/position-statements-reports/ statistics. Accessed November 2021.

2. Lanting LC et al. Ethnic Differences in Mortality, End-Stage Complications, and Quality of Care Among Diabetic Patients. Diabetes Care 2005 Sept; 28(9): 2280-2288.

Find out more at lilly.co.uk/diseaseareas/diabetes

In sporting environments, it’s important to make sure everyone knows about your situation and that they know what to do in an emergency. ~Jordan Thompson, Diabetes UK Ambassador

READ MORE AT HEALTHAWARENESS.CO.UK

MEDIAPLANET

07

A PROMOTIONAL SUPPLEMENT DISTRIBUTED ON BEHALF OF MEDIAPLANET, WHICH TAKES SOLE RESPONSIBILITY FOR ITS CONTENTS

Tubeless insulin delivery.

Simplify Life

Hannah McCook

TM

PODDER TM SINCE 2018

The Omnipod DASH® System is a tubeless insulin pump that comprises of a small, waterproof* Pod controlled by a smartphonelike device (Personal Diabetes Manager).

With personalised insulin delivery and no multiple daily injections it may help simplify your T1 diabetes management.

ORDER A FREE SAMPLE POD† Omnipod.com

Actual size of Pod

Speak to your Healthcare Provider to assess if the Omnipod DASH® System is a good option for you.

Insulet_UK

OmnipodUK

omnipoduk

*The Pod has a waterproof IP28 rating for up to 7.6 metres for up to 60 minutes. The PDM is not waterproof. †The sample Pod is a needle-free Pod that does not deliver insulin. PDM is not included.

Screen image is an example, for illustrative purposes only. ©2021 Insulet Corporation. Omnipod, the Omnipod logo, DASH, the DASH logo, Simplify Life and Podder are trademarks or registered trademarks of Insulet Corporation in the USA and other various jurisdictions. All rights reserved. Glooko is a trademark of Glooko, Inc. and used with permission. All other trademarks are the property of their respective owners.

The use of third party trademarks does not constitute an endorsement or imply a relationship or other affiliation. Insulet Netherlands BV Stadsplateau 7, 3521 AZ Utrecht, Pays-Bas. INS-ODS-08-2021-00045 V1-Pt3

08

MEDIAPLANET

EUDASH-Adult-ENG-INS-ODS-08-2021-00045 V1_265x330.indd 1

READ MORE AT HEALTHAWARENESS.CO.UK 14/10/2021 16:20

A PROMOTIONAL SUPPLEMENT DISTRIBUTED ON BEHALF OF MEDIAPLANET, WHICH TAKES SOLE RESPONSIBILITY FOR ITS CONTENTS

Advertorial

How Khalid Keshta’s career change made him a winner Diabetes technology is improving the quality of life for people with type 1 diabetes Khalid started managing his diabetes on multiple daily injections (MDI) but moved away from MDI and onto an insulin pump. He says, “I was happy with it at the time, but because of the tubing and the type of exercise I did, I had to take it off to train, so it ended up feeling like too much hassle.

Then I went to a JDRF event and saw someone with something on their arm; I just thought it was a type of sensor, but they told me it was an Omnipod®: a tubeless, wireless insulin pump.

That really got my attention.

Paid for by Insulet

Image provided by Insulet

I had an extremely helpful health care provider and they asked the commissioner about getting me an Omnipod DASH® System.

Khalid discusses his journey with type 1 diabetes and, with the help of diabetes technology, refuses to let it stop him pursuing his athletic career.

K INTERVIEW WITH Khalid Keshta Bodybuilder and Omnipod® Ambassador WRITTEN BY Sue Marshall

halid Keshta was diagnosed with type 1 diabetes in 2011, on the day of his 18th birthday. He remembers it all very clearly, “I started to lose a lot of weight, yet I was athletic. I used to play football, but I’d get really thirsty and I was running to the loo all the time.”

“My parents bought a blood test meter and my whole family did a blood test. They all came back with a reading, but for me it just kept reading ‘error’. We decided to go to A&E and my blood sugar reading was 47mmol/L. The doctor told me that if it wasn’t for the immense amount of water I’d been drinking and urinating constantly, I would have been in a diabetic coma or possibly dead.”

READ MORE AT HEALTHAWARENESS.CO.UK

Maintaining an active lifestyle Khalid had been contemplating a career as a footballer but after he broke his knee and tore some ligaments his intended career was over.

He refused to be inactive and started to go to the gym, he says “I began to see changes in my body shape, then after a few years people said, why don’t you compete? I’d not been interested in being a competitive bodybuilder until I realised I could be different, I could compete as a bodybuilder with type 1 diabetes. It is a hard sport, but if I could compete on stage and do well and at the same time raise awareness, I could help show people that you can do anything.”

In 2017, Khalid entered his first competition and won.

“I had an extremely helpful health care provider and they asked the commissioner about getting me an Omnipod DASH® System.”

The main benefit, he says, is that it’s tubeless. “But I can also use temporary basal rates, which are handy especially during or after exercise. I also feel like it’s easier to calculate my doses using the bolus calculator on the PDM (personal diabetes manager) rather than on MDI.” Now Khalid continues to train, compete and coach others as a personal trainer. He uses social media to help raise awareness of what type 1 diabetes is. He says, “People ask me what’s on my arm, and I tell them it’s my insulin pump. I love being different and wearing my Omnipod®, especially on my abdomen when in a competition - I don’t want to hide it.

People comment on the muscles, then the Pod and then they ask, ‘how can you do this and have type 1 diabetes?’ and I say, ‘You can be whatever you want to be’.”

Khalid is an Omnipod® Ambassador and has an ongoing commercial relationship with Insulet. This Omnipod DASH® System user testimonial relates to an account of an individual’s response to treatment with the Omnipod DASH® System. However, the individuals’ response does not provide any indication, guide, warranty or guarantee as to the response other persons may have when using the Omnipod DASH® System. The response other persons have could be different. Suitability for the Omnipod DASH® Insulin Management System should be discussed with a qualified Healthcare Provider. Refer to the Omnipod DASH® Insulin Management System User Guide for complete safety information including indications, contraindications, warnings, cautions, and instructions.

Scan the QR code to find out more

MEDIAPLANET

09

A PROMOTIONAL SUPPLEMENT DISTRIBUTED ON BEHALF OF MEDIAPLANET, WHICH TAKES SOLE RESPONSIBILITY FOR ITS CONTENTS

Without sufficient action to address the situation, we predict 643 million people will have diabetes by 2030.

One in 10 people live with diabetes The rates of diabetes globally are at an unprecedented level. Urgent action is needed to control diabetes and provide access to care.

T WRITTEN BY Professor Andrew Boulton President, The International Diabetes Federation

he findings from the IDF Diabetes Atlas 10th edition highlight the alarming growth in the prevalence of diabetes around the world. More than 537 million adults (one in 10) are now living with diabetes worldwide — a rise of 16% (74 million) in the past two years. Without sufficient action to address the situation, we predict 643 million people will have diabetes by 2030 (11.3% of the population).

Spiralling out of control I wish I could report that in the past two decades we have witnessed decisive action to tackle diabetes. I wish I could share the news that all people living with diabetes worldwide can access and afford the care they need. I wish I could declare that 100 years after its discovery, therapeutic insulin is now within reach of all those who need it to survive. Unfortunately, I cannot. Instead, I must repeat the message that diabetes rates are at an unprecedented level, spiralling out of control.

Diabetes ranks among the top 10 global causes of death, so why is not enough being done to prevent diabetes and its complications and provide the best available care to people with the condition?

Much can be done to reduce the impact of

diabetes. Evidence suggests that type 2 diabetes can often be prevented, in some cases reversed, while early diagnosis and access to appropriate care for all types of diabetes can avoid or delay complications for people living with the condition.

Rays of hope There are some rays of hope. The centenary of the discovery of insulin has attracted greater attention to the diabetes cause. In April, the World Health Organization launched its Global Diabetes Compact, marking an increased focus on diabetes. Soon after, a landmark Resolution was agreed by the World Health Assembly, highlighting the importance of prevention, diagnosis and control of diabetes. These are important steps towards addressing the continued and rapid rise of diabetes prevalence, particularly in countries that do not have a national diabetes plan.

I must repeat the message that diabetes rates are at an unprecedented level, spiralling out of control.

10

MEDIAPLANET

Support our call Words must now be turned into action. If not now, when? The theme chosen by the International Diabetes Federation for diabetes awareness month and World Diabetes Day is access to diabetes care.

Find out more and support our call at worlddiabetesday.org

READ MORE AT HEALTHAWARENESS.CO.UK

A PROMOTIONAL SUPPLEMENT DISTRIBUTED ON BEHALF OF MEDIAPLANET, WHICH TAKES SOLE RESPONSIBILITY FOR ITS CONTENTS

Community action – a winning formula to defeat T2D? Our communities shape our lives, our behaviours and even our health. Can we harness that power to build environments that promote better health and diabetes outcomes for all?

Image provided by Novo Nordisk

T WRITTEN BY Pinder Sahota Corporate Vice President and General Manager, Novo Nordisk UK

Our purpose is to defeat diabetes – learn more about the steps we are taking at: novonordisk.co.uk

he risk of developing type 2 diabetes is driven by complex environmental and cultural factors – including how connected we are to our communities.1 Novo Nordisk is focused on accelerating innovation to defeat diabetes, and we recognise the importance of our partnerships with grassroots organisations to address those crucial social factors.

Local action for a global challenge By 2030, it is estimated that one in 10 people will live with diabetes in the UK,2 with around 90% having type 2 diabetes.3 The scale of this challenge requires collaboration across sectors and disciplines, focused within communities.

We recognise that there is no ‘one size fits all’ approach to type 2 diabetes management and prevention. Cities Changing Diabetes is a global initiative Novo Nordisk launched alongside University College London (UCL) and Steno Diabetes Center in Copenhagen, to address the increase in type 2 diabetes in urban areas. In 2017, Leicester became the first UK city to join the programme. Manchester followed in 2019.

Reaching communities within communities In the UK, type 2 diabetes is between 2.5 to 5 times more common in people of South Asian ethnicity than people of white European ethnicity.4 Leicester is one of the most ethnically diverse cities in England, so health interventions must be culturally relevant and accessible. Working with the right partners – with the right expertise and influence to drive change – is essential.

The Leicester Cities Changing Diabetes programme, funded by and developed in collaboration between Leicester Diabetes Centre and Novo Nordisk, engages a range of local partners, from Leicester’s Interfaith Council to the Centre for Ethnic Health Research, professional sports clubs, public health and NHS colleagues, to improve health. Initiatives to help address type 2 diabetes in Leicester include ‘Healthy Goals’ – a programme of interactive lifestyle education and physical activity tailored for the South Asian community.

READ MORE AT HEALTHAWARENESS.CO.UK

To ensure access for all, this includes dedicated all-female sessions to empower women and enable them to look after their health in a welcoming environment.

Paid for by Novo Nordisk

Tackling diabetes in specific groups Research has identified a significant gap in men’s health awareness and use of primary health services5 – which can lead to late type 2 diabetes diagnosis. To tackle this, we need to go where these men are likely to be – for example at the football. Working with Everton in the Community, our specialist diabetes nurses have offered pre-match diabetes testing at some of the club’s home games, with plans to do so again. In Leicester, the Cities Changing Diabetes team has also supported community screening events to help identify those at risk of type 2 diabetes, with over 800 people screened already.

With the community, for the community We believe that bringing community partners together to collectively support better health is the way to make a sustainable difference to people living with type 2 diabetes.

This requires an ongoing commitment to become truly embedded in communities, and a willingness to be led by and for their residents. The link between type 2 diabetes and poorer COVID-196 outcomes has made it even more critical to support at-risk communities and Cities Changing Diabetes, and other initiatives, aim to do just that – to support the future health of our nation.

References 1. Schram, M.T., Assendelft, W.J.J., van Tilburg, T.G. et al. Social networks and type 2 diabetes: a narrative review. Diabetologia. 2021;64:1905–1916 2. Diabetes UK. 1-in-10 adults living with diabetes by 2030. Available from: https://www.diabetes.org. uk/about_us/news/1-10-adults-living-diabetes-2030. [Accessed October 2021] 3. Diabetes UK. Diabetes Statistics. Available from: https://www.diabetes.org.uk/professionals/ position-statements-reports/statistics [Accessed October 2021] 4. English S, Tippu Z, Chan T et al. Type 2 diabetes prevalence among people of South Asian ethnicity in the UK. Diabetes & Primary Care. 2016;18:28–32 5. Pringle, A., Zwolinsky, S., McKenna, J. et al. Health improvement for men and hard-to-engage-men delivered in English Premier League football clubs. Health Education Research. 2014;29:503-520.

6. Barron E et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. The Lancet Diabetes & Endocrinology. 2020;8(10):813-822

Read more about Leicester Cities Changing Diabetes here: leicesterchanging diabetes.com

MEDIAPLANET

11

A PROMOTIONAL SUPPLEMENT DISTRIBUTED ON BEHALF OF MEDIAPLANET, WHICH TAKES SOLE RESPONSIBILITY FOR ITS CONTENTS

Ava, Dexcom Warrior since 2020

mmol/L

More time to play Live life with fewer interruptions.

The Dexcom G6 Continuous Glucose Monitoring (CGM) System sends real-time glucose readings to a smartphone,† so with a quick glance you can know where their glucose is headed and how fast – all with zero fingersticks* or scanning.

Smart devices sold separately.†

Get their glucose data and alerts on your phone with Dexcom Follow,‡ so you can both get on with life.

EXPERIENCE THE DEXCOM DIFFERENCE Visit dexcom.com/kids-uk

*If your glucose alerts and readings from the Dexcom G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions. †For a list of compatible smart devices, please visit www.dexcom.com/compatibility. Smart device required to display readings on watch. ‡Internet connectivity required for data sharing. Following requires the use of the Follow App. Followers should always confirm readings on the Dexcom G6 App or Receiver before making treatment decisions. Ava is a sponsored spokesperson of Dexcom. Dexcom, Dexcom G6, Dexcom Follow, Dexcom Share, and Dexcom CLARITY are registered trademarks of Dexcom, Inc. in the U.S. and may be in other countries. © 2021 Dexcom International Ltd. All rights reserved. Dexcom International Ltd and its affiliated European entities. This product is covered

by U.S. patent. www.dexcom.com | +1.858.200.0200 | Dexcom, Inc. 6340 Sequence Drive San Diego, CA 92121 USA | MDSS GmbH Schiffgraben 41 30175 Hannover, Germany. LBL022068 Rev001.

12

DEX2469 - Balance Magazine Winter - Guardian Mag Full Page 265x330mm_ART.indd 2

MEDIAPLANET

01/11/2021 16:58

READ MORE AT HEALTHAWARENESS.CO.UK